1Rybak MJ . The pharmacokinetic and pharmacodynamic properties of vancomycin [ J ] . Clin Infect Dis, 2006 ;42 ( Suppl. ) : S35 -S39.
2Laiprasert J, Klein K, Mueller BA, et al. Transplacental passage of vancomycin in noninfected term pregnant women [ J ]. Obstet Gynecol, 2007; 109:1105-1110.
3de Jesu's Valle M J, Lo'pez FG, Hurle AD, et al. Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung [ J ]. Antimicrob Agents Chemother, 2007 ; 51 : 3771 - 3774.
4Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic pharmacodynamic surrogate markers to outcome [J]. Clin Pharmacokinet, 1995 ;28 : 143 - 160.
5Hermsen ED. Pharmacokinetic Training packet for Pharmacists [DB/OL]. http ://intranet. nebraskamed. com/careers/education/asp/pdfs/ pk - training packet, pdf. ,2007 - 09 - 12.
6Duffull SB , Begg EJ, Chambers S T,et al. Efficacies of different van- comycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model[ J ]. Antimicrob Agents Chemother, 1994 ; 38 : 2480 - 2482.
7Jeffres MN , Isakow W, Doherty JA, et al. Predictors of mortality for methicillin - resistant Staphylococcus aureus health - care - associated Pneumonia: specific evaluation of vancomycin pharmacokinetic indices [ J ]. Chest, 2006 ; 130:947 - 955.
8Wang JT, Fang CT, Chen YC. Necessity of a loading dose when using vancomycin in critically ill patients [ J ]. J Antimicrob Chemother, 2001 ;47 : 246.
9Jeffres N , Isakow W, Doherty JA ,et al. A retrospective analysis of pos- sible renal toxicity associated with vancomycin in patients with health care - associated methicillin - resistant Staphylococcus aureus Pneumonia[J]. Clin Ther, 2007;29:1107 - 1115.
10Lucksiri A, Scott MK, Mueller BA, et al. CAHP - 210 dialyzer influence on intra -dialytic vancomycin removal [ J ]. Nephrol Dial Transplant, 2002; 17:1649 - 1654.
